866-997-4948(US-Canada Toll Free)

Neuroendocrine Carcinoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 25 Pages


Global Markets Directs, \'Neuroendocrine Carcinoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Carcinoma. 

Neuroendocrine Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Neuroendocrine Carcinoma.
  • A review of the Neuroendocrine Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Neuroendocrine Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Neuroendocrine Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Neuroendocrine Carcinoma Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Neuroendocrine Carcinoma 6
Neuroendocrine Carcinoma Therapeutics under Development by Companies 8
Early Clinical Stage Products 9
Comparative Analysis 9
Neuroendocrine Carcinoma Therapeutics - Products under Development by Companies 10
Companies Involved in Neuroendocrine Carcinoma Therapeutics Development 11
Novartis AG 11
Neuroendocrine Carcinoma - Therapeutics Assessment 12
Assessment by Monotherapy Products 12
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Drug Profiles 17
pasireotide - Drug Profile 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Neuroendocrine Carcinoma Therapeutics - Drug Profile Updates 20
Neuroendocrine Carcinoma Therapeutics - Dormant Products 23

Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Table


Number of Products Under Development for Neuroendocrine Carcinoma, H1 2013 6
Products under Development for Neuroendocrine Carcinoma - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Early Clinical Stage Development, H1 2013 9
Products under Development by Companies, H1 2013 10
Novartis AG, H1 2013 11
Assessment by Monotherapy Products, H1 2013 12
Assessment by Stage and Route of Administration, H1 2013 14
Assessment by Stage and Molecule Type, H1 2013 16
Neuroendocrine Carcinoma Therapeutics - Drug Profile Updates 20
Neuroendocrine Carcinoma Therapeutics - Dormant Products 23

List of Chart


Number of Products under Development for Neuroendocrine Carcinoma, H1 2013 6
Products under Development for Neuroendocrine Carcinoma - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Early Clinical Stage Products, H1 2013 9
Assessment by Monotherapy Products, H1 2013 12
Assessment by Route of Administration, H1 2013 13
Assessment by Stage and Route of Administration, H1 2013 14
Assessment by Molecule Type, H1 2013 15
Assessment by Stage and Molecule Type, H1 2013 16

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *